AbbVie or Allergan: Which Is a Better Pick in June?

AbbVie or Allergan: Which Is a Better Pick in June?

AbbVie (ABBV) is down 14.69%, and Allergan (AGN) is down 13.41% in 2019 on a year-to-date basis. While concerns about the anticipated generic erosion of its flagship Humira franchise have proved to be a drag for AbbVie, Allergan is being increasingly criticized for a couple of reasons.